Stockreport

CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute...

CSL LTD SP/ADR  (CSLLY) 
NASDAQ:AMEX Investor Relations: csl.com/investors
PDF offers the first pre-filled pen presentation enabling once-monthly subcutaneous administration The approval is based on the results of the international pivotal Phase [Read more]